Who Is Eligible to Join Calibrate? A Complete Medical Guide to GLP-1 Weight-Loss Programs

What Are Calibrate's Core BMI Requirements?

Calibrate uses the same BMI thresholds written into FDA labeling for GLP-1 receptor agonists. Adults with a BMI at or above 30 qualify without needing any additional diagnosis. Adults with a BMI between 27 and 29.9 qualify if they carry at least one weight-related comorbidity.

The 30 BMI Threshold (No Comorbidity Required)

A BMI of 30 or above meets the definition of obesity under CDC classification, affecting approximately 41.9% of U.S. Adults as of the most recent National Health and Nutrition Examination Survey data [1]. At this threshold, the cardiovascular and metabolic risks of excess adiposity are well-documented. The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with established cardiovascular disease and a BMI of 27 or above, even without a diabetes diagnosis [2]. Calibrate's threshold of 30 for the no-comorbidity path is therefore conservative relative to emerging trial evidence.

The 27 BMI Threshold (With Comorbidity)

Applicants with a BMI between 27 and 29.9 must document at least one qualifying condition. The FDA approved this lower threshold for semaglutide 2.4 mg (Wegovy) in June 2021 and for tirzepatide 15 mg (Zepbound) in November 2023 based on key trial data showing meaningful weight reduction and cardiometabolic benefit even in individuals classified as overweight rather than obese [3][4].

Qualifying comorbidities typically include:

• Type 2 diabetes mellitus
• Hypertension (treated or untreated)
• Dyslipidemia (elevated LDL, low HDL, or elevated triglycerides)
• Obstructive sleep apnea confirmed by polysomnography or home sleep test
• Cardiovascular disease (coronary artery disease, prior MI, prior stroke)

The STEP-1 trial (N=1,961) showed that adults meeting these BMI thresholds achieved a mean body weight reduction of 14.9% with semaglutide 2.4 mg at 68 weeks versus 2.4% with placebo [5]. The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks versus 3.1% with placebo [6].

BMI Calculation and Documentation

BMI is calculated as weight in kilograms divided by height in meters squared. Calibrate's intake process collects self-reported height and weight, and the assigned physician may request recent laboratory work or a previous provider note to confirm measurements before prescribing.

Who Is Automatically Disqualified From Calibrate?

Several absolute contraindications apply regardless of BMI or comorbidity status. These mirror contraindications listed in the FDA-approved prescribing information for semaglutide and tirzepatide [3][4].

Thyroid Cancer History or Risk

Anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2) cannot participate. GLP-1 receptor agonists carry an FDA black-box warning on this point. In rodent studies, these agents caused dose-dependent thyroid C-cell tumors, and although a direct causal link in humans has not been confirmed, the FDA considers the risk sufficient to contraindicate use in this population [3]. A 2023 observational study published in JAMA Network Open found a small but statistically significant association between GLP-1 receptor agonist use and thyroid cancer risk (HR 1.58, 95% CI 1.27 to 1.95) compared with non-use in people with type 2 diabetes, though methodological limitations mean causality remains uncertain [7].

Pregnancy and Breastfeeding

Pregnancy is an absolute exclusion. Animal reproductive studies have shown fetal harm at clinically relevant exposures to semaglutide, and the drug is rated Pregnancy Category not assigned with an explicit warning against use [3]. The American College of Obstetricians and Gynecologists recommends against GLP-1 receptor agonist use during pregnancy given the absence of adequate human safety data [8]. Women of reproductive age considering Calibrate should use effective contraception during treatment, as rapid weight loss can alter contraceptive efficacy and menstrual cycle regularity.

Active Eating Disorders

Current anorexia nervosa or bulimia nervosa disqualifies applicants. GLP-1 receptor agonists suppress appetite significantly. Prescribing appetite-suppressing agents to someone already restricting intake dangerously could compound harm. The American Psychiatric Association's DSM-5-TR criteria define anorexia nervosa partly by restriction of energy intake leading to significantly low body weight [9]. Calibrate's screening asks about eating disorder history; a current diagnosis or active treatment for one of these conditions results in automatic exclusion.

Other Medical Exclusions

Additional conditions that may trigger exclusion or require physician review include:

• Pancreatitis (acute or chronic history), given GLP-1 receptor agonist association with pancreatitis risk noted in prescribing information [3]
• Severe gastroparesis, since GLP-1 agents slow gastric emptying and can worsen this condition
• Active gallbladder disease, as rapid weight loss and GLP-1 therapy both independently increase cholelithiasis risk [5]
• Severe renal impairment (eGFR <15 mL/min/1.73 m²) or dialysis dependence
• Type 1 diabetes mellitus, which requires a separate clinical management framework

Age and Geographic Requirements

Calibrate currently serves adults 18 years and older. No maximum age cutoff appears in published eligibility criteria, though older adults with multiple comorbidities may require additional physician review before a prescription is issued.

Geographic Coverage

Calibrate operates as a telehealth platform licensed to prescribe in most U.S. States. Specific state availability can change as licensing expands. Applicants outside the United States are not currently eligible. State-level telemedicine prescribing laws govern whether an out-of-state physician can issue a controlled or non-controlled prescription, and GLP-1 receptor agonists are not scheduled substances, which simplifies cross-state prescribing in most jurisdictions.

Age Considerations for Older Adults

Adults aged 65 and older may have altered GLP-1 receptor agonist pharmacokinetics. A population pharmacokinetic analysis of semaglutide showed no clinically meaningful difference in drug exposure by age, though older patients experienced higher rates of gastrointestinal adverse events [10]. Calibrate's physicians assess overall health status and medication burden before prescribing in this population.

How Does Insurance Affect Eligibility?

Insurance coverage does not determine clinical eligibility for Calibrate, but it heavily influences out-of-pocket cost and therefore practical access.

Prior Authorization Requirements

Most commercial insurance plans require prior authorization before covering Wegovy or Zepbound. The prior authorization process typically demands documentation of a qualifying BMI, presence of comorbidities, and evidence that lifestyle interventions have been attempted. Calibrate's team submits prior authorization paperwork on behalf of members, but approval is never guaranteed.

Medicare and Medicaid Coverage

The Inflation Reduction Act of 2022 opened a pathway for Medicare to negotiate drug prices, and the Treat and Reduce Obesity Act has been proposed repeatedly in Congress to expand Medicare Part D coverage of anti-obesity medications. As of early 2025, Medicare Part D covers semaglutide 2.4 mg only when prescribed for cardiovascular risk reduction under the SELECT trial indication in patients with established cardiovascular disease and obesity, not for weight loss alone [2][11]. Medicaid coverage varies by state. This creates a coverage gap for many older adults seeking Calibrate purely for metabolic health.

Cash-Pay Costs

Without insurance coverage, GLP-1 receptor agonists carry list prices exceeding $1,300 per month for Wegovy and $1,060 per month for Zepbound as of 2024 manufacturer pricing. Calibrate's program fee covers the coaching, physician visits, and prior authorization support, but the drug cost itself is separate and can represent the primary financial barrier to enrollment.

What Medical Tests or Records Does Calibrate Require at Enrollment?

Calibrate's intake process is designed as an asynchronous telehealth evaluation. Applicants complete a detailed health history questionnaire covering current medications, diagnoses, surgical history, and family history relevant to GLP-1 contraindications.

Laboratory Requirements

Calibrate typically requests a recent metabolic panel and HbA1c at baseline. These labs serve several clinical functions. First, they confirm the presence or absence of type 2 diabetes, which can affect both eligibility (qualifying comorbidity at BMI 27 to 29.9) and the specific GLP-1 agent selected. Second, they establish baseline renal and hepatic function before initiating a drug that undergoes renal clearance. Third, abnormal lipids documented on a lipid panel can serve as the qualifying comorbidity for the lower BMI threshold. Per American Diabetes Association Standards of Care, HbA1c at or above 6.5% on two separate occasions confirms a diabetes diagnosis [12].

Physician Review Timeline

After submitting the health history and any requested labs, applicants are reviewed by a Calibrate-affiliated physician. This review is asynchronous in most cases. The physician determines final prescribing eligibility and selects the initial GLP-1 agent and starting dose.

How Does Calibrate's Eligibility Compare to FDA Labeling?

Calibrate's eligibility criteria align closely with FDA-approved indications for the two agents most commonly used in the program.

Semaglutide 2.4 mg (Wegovy) FDA Indication

The FDA approved Wegovy on June 4, 2021, for chronic weight management in adults with an initial BMI of 30 or above, or 27 or above with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity [3]. The STEP-4 trial (N=803) showed that adults who discontinued semaglutide after 20 weeks regained two-thirds of their prior weight loss within one year, supporting the chronic-use framing baked into Calibrate's 12-month minimum commitment [13].

The prescribing information states: "Limitations of use: Calibrate has not been studied in patients with a history of pancreatitis. Consider other anti-obesity therapies in patients with a history of pancreatitis." [3]

Tirzepatide 15 mg (Zepbound) FDA Indication

The FDA approved Zepbound on November 8, 2023, for adults with a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity [4]. SURMOUNT-1 showed that at the 15 mg dose, 37.1% of participants achieved at least 20% body weight loss versus 3.0% with placebo at 72 weeks [6]. This response rate is higher than that seen with semaglutide in head-to-head modeling, though no randomized controlled trial has directly compared the two agents at approved doses in a weight-loss primary endpoint design.

Where Calibrate Diverges From Raw FDA Labeling

Calibrate adds program-level requirements that go beyond FDA labeling: the 12-month commitment structure, mandatory health coaching sessions, and behavioral curriculum. From a purely medical standpoint, FDA labeling does not require a coaching program for prescription; Calibrate's program design bundles these elements as a condition of program participation, not as a regulatory requirement.

What Happens During the 12-Month Program After Enrollment?

Enrollment triggers a structured sequence of physician visits, coaching sessions, and dose titration.

Dose Titration Schedule

GLP-1 receptor agonists require gradual dose escalation to minimize gastrointestinal side effects. For semaglutide 2.4 mg, the prescribing information specifies starting at 0.25 mg weekly for 4 weeks, escalating by 0.25 mg every 4 weeks to reach 2.4 mg by week 16 to 20 [3]. Tirzepatide follows a similar step-up schedule, starting at 2.5 mg weekly and escalating by 2.5 mg every 4 weeks to a maintenance dose between 5 mg and 15 mg depending on tolerability and response [4].

Monitoring During Treatment

Quarterly physician check-ins assess weight response, side effect burden, blood pressure, and any emerging contraindications. The American Association of Clinical Endocrinology's 2023 obesity clinical practice guidelines recommend monitoring HbA1c, lipids, and blood pressure at baseline, 3 months, and 12 months in patients on anti-obesity pharmacotherapy [14]. Calibrate's check-in schedule maps to this frequency.

Stopping Rules

Physicians may discontinue the GLP-1 agent if the patient achieves <5% weight loss after 16 weeks at a maintenance dose, which is the threshold used in clinical trials and endorsed by AACE guidelines to identify non-responders [14]. Weight regain after stopping is expected, as shown by STEP-4 data, and discontinuation decisions should be made collaboratively.

Frequently Asked Questions